Chairman John Moolenaar, Ranking Member Raja Krishnamoorthi, and Representative Neal Dunn have addressed a letter to Secretary of Commerce Gina Raimondo. The House Select Committee on the Chinese Communist Party members are urging for updated regulations that would require a license before engaging with Chinese military hospitals for clinical trials.

In mid-2024, these lawmakers requested information from the FDA concerning clinical trials conducted at Chinese military hospitals. They also inquired about FDA site visits in China and trials happening in Xinjiang, where there is an ongoing genocide against the Uyghur population by the CCP.

The lawmakers expressed concerns over the potential use of biotechnology by the Chinese Communist Party against the United States. They stated, "While the chemical compounds of drugs in development and related IP are not export controlled, [the Bureau of Industry and Security’s] proposed update to toughen military end-user and end-use controls could be strengthened to specifically state that cooperation with PLA medical institutions for the purpose of clinical trials is subject to a licensing requirement."

Furthermore, they recommended changes to define “Military End User” more explicitly. They wrote, “Specifically, we recommend updating the definition of 'Military End User' to state medical infrastructure owned or operated by the national armed services of the PRC and other countries as appropriate constitutes a military end-use if a U.S. person is seeking to engage with the institution to conduct a clinical trial.”

Viewers can access the lawmakers’ letter through provided links.